Evidence map›Paper›PMID 35463727›Full record

ArticleIranian journal of pathology2022

Diagnostic and Therapeutic Implications of Sortilin Expressed on the Surface of Bladder Carcinoma Cells.

Ali-Ahmad Bayat, Niloufar Sadeghi, Ghazaleh Fazli, Mohammad Reza Nowroozi, Solmaz Ohadian Moghadam, Amin Radmanesh, Mohammadjavad Hedayatshodeh, Ali Reza Sarrafzadeh, Omid Zarei, Fatemeh Ghaemimanesh and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Ali-Ahmad BayatMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Niloufar SadeghiMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Ghazaleh FazliMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Mohammad Reza NowrooziUro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Solmaz Ohadian MoghadamUro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Amin RadmaneshLegal Medicine Research Center, Legal Medicine Organization, Tehran, Iran.
Mohammadjavad HedayatshodehLegal Medicine Research Center, Legal Medicine Organization, Tehran, Iran.
Ali Reza SarrafzadehDepartment of Pathology, Khatam Al Anbia Hospital, Tehran, Iran.
Omid ZareiCellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Fatemeh GhaemimaneshMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Hodjattallah RabbaniMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Academic Center for Education, Culture and Research · IRIranian Legal Medicine Organization · IRTehran University of Medical Sciences · IRKhatam University · IRKurdistan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Objective: Cell surface expression of sortilin in different types of cancer signifies it as a therapeutic target for cancer therapy. The aim of this study was to detect sortilin expression in bladder cancer cells using an anti-sortilin monoclonal antibody (mAb) to evaluate sortilin as a target for developing diagnostic and therapeutic agents against bladder carcinoma. Methods: The protein expression of sortilin in bladder cancer tissues and cell lines (5637 and EJ138) was investigated by immunohistochemistry (IHC), immune-cytochemistry (ICC), and flow cytometry. Furthermore, the capability of anti-sortilin mAb in apoptosis induction in bladder cancer cells was evaluated. Results: A high expression level was observed in bladder carcinoma tissues ( Conclusion: The overexpression of sortilin in bladder tumor cells and its potential in inducing apoptosis via directed targeting with the specific monoclonal antibody may represent this protein as a potential candidate of targeted therapy in bladder carcinoma.

Indexed as

Bladder cancerFlow cytometryMonoclonal antibodySortilin

Identifiers

PMID35463727
PMCPMC9013872
OpenAlexW4225536286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.